Urosphere will attend the toulouse oncoweek, to be held in toulouse, france, february 03-05, 2016.
We will have an oral communication on "Optical imaging in preclinical tumour models: helpful or pitfall?” on Friday, February 5th, 13:00-14:15
If you wish to meet Urosphere's managers during the meeting, please contact us.
Urosphere and Ambiotis sign a strategic collaboration agreement
Urosphere and Ambiotis another Contract Research Organization, based in Toulouse, France announce a strategic partnership to broaden and strenghten their respective activities. Under this agreement, the two companies intend to combine their skills to offer an even more integrated approach to their customers. UROSPHERE will indeed bring its expertise in building physiological and pathological animal models within the uro-genital, gastro-intestinal and oncological areas while Ambiotis will offer its expertise in the molecular characterization of such models (inflammatory and pain mediators).
Urosphere is pleased to announce another step in its commitment to the highest quality standards. Urosphere obtained the certification of its Quality Management System (QMS) ISO 9001: 2008 provided by Lloyd's Register Quality Assurance (LRQA), a world’s leading provider of certifications.
“Today, we become the first CRO specialized in preclinical pharmacology in the field of urogenital pathologies. We provide to our customers an internationally recognized certification of its QMS not only for the scientific side of our activity but also for the whole organization.” said Dr. Philippe LLUEL, Chief Executive Officer.
Demonstrating a real commitment to service quality, Urosphere applies on a daily bases the following principles: - To provide customers the competency of our staff and high level of expertise, - To listen and to adapt to specific needs, - To guarantee a perfect traceability of our data, - To become a privileged partner.
Click here to see our certificate of approval: ISO 9001 certification
Colorectal cancers and those of the urological sphere (prostate and bladder) are among the five most common cancers. A chronic inflammatory condition predisposes to the appearance of some of these cancers (colon, prostate). Today, the available experimental models poorly simulate the biological reality and function of the body, which makes it particularly difficult to develop new drugs. The objective of the Organocan 2 project is to develop cell models in 3-dimensional (organoid) of colon, bladder and prostate representing the molecular and cellular complexity of human organs. This tool will implement additional efficiency filter to improve the selection of drug candidates, but also to develop personalized medicine tools (therapeutic and diagnostic tests) and to understand the fundamental mechanisms of carcinogenesis and inflammation. This project is based on the complementarity of four partners: an innovative SME specialized in the field of urology (UROsphere), an Inserm team (Team Dr. N. Vergnolle U1043), a pharmaceutical company (Pierre Fabre) and the Toulouse University Hospital (CHU Toulouse).